Who are COP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Durezol, Arnuity Ellipta, Omnaris, Omnaris, Mifeprex, Lotemax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cop.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

COP — Competitive Intelligence Brief

COP (COP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid. Area: Respiratory.

marketed Corticosteroid Glucocorticoid receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

COP (COP) — Acrotech Biopharma Inc.. COP is a corticosteroid that reduces inflammation and swelling in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
COP TARGET	COP	Acrotech Biopharma Inc.	marketed	Corticosteroid	Glucocorticoid receptor
Durezol	DIFLUPREDNATE	Novartis	marketed	difluprednate	Glucocorticoid receptor	2008-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	marketed	Corticosteroid	Glucocorticoid receptor	2007-01-01
Omnaris	Alvesco	Takeda Gmbh	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	CICLESONIDE	Covis	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Mifeprex	MIFEPRISTONE	Corcept Therap	marketed	Progestin Antagonist [EPC]	Glucocorticoid receptor	2000-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	marketed	Corticosteroid	Glucocorticoid receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-02-01 — Omnaris · 8371292 · US
2033-05-03 — Lotemax · 9056057 · Formulation · US
2033-05-03 — Lotemax · 9532955 · Method of Use · US
2033-05-03 — Lotemax · 10058511 · Formulation · US
2033-05-03 — Lotemax · 11219596 · Method of Use · US
2033-05-03 — Lotemax · 11219597 · Method of Use · US
2033-05-03 — Lotemax · 11596599 · Method of Use · US
2033-05-03 — Lotemax · 10857096 · Method of Use · US
2033-05-03 — Lotemax · 10864219 · Method of Use · US
2033-05-03 — Lotemax · 10945948 · Method of Use · US
2033-05-03 — Lotemax · 10940108 · Method of Use · US
2033-05-03 — Lotemax · 9737491 · Method of Use · US
2033-05-03 — Lotemax · 9827191 · Formulation · US
2033-05-03 — Lotemax · 11872318 · Formulation · US
2033-05-03 — Lotemax · 9393213 · Formulation · US
2033-05-03 — Lotemax · 10646436 · Formulation · US
2033-05-03 — Lotemax · 10993908 · Method of Use · US
2033-05-03 — Lotemax · 12115246 · Formulation · US
2033-05-03 — Lotemax · 10688045 · Formulation · US
2033-05-03 — Lotemax · 11642317 · Formulation · US
2033-05-03 — Lotemax · 10646437 · Formulation · US
2036-01-26 — Lotemax · 11534395 · Formulation · US
2036-12-23 — Lotemax · 10596107 · Formulation · US

Sponsor landscape (Corticosteroid class)

· 22 drugs in this class
Pfizer · 9 drugs in this class
Chiesi Farmaceutici S.p.A. · 6 drugs in this class
Assistance Publique - Hôpitaux de Paris · 6 drugs in this class
Merck & Co. · 5 drugs in this class
LEO Pharma · 4 drugs in this class
Allergan · 4 drugs in this class
AbbVie · 4 drugs in this class
Bristol-Myers Squibb · 3 drugs in this class
Bausch Health · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COP — Competitive Intelligence Brief. https://druglandscape.com/ci/cop. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab